02nd week of 2022 patent applcation highlights part 10 |
Patent application number | Title | Published |
20220008467 | T-Cell Modulatory Multimeric Polypeptides with Conjugation Sites and Methods of Use Thereof - The present disclosure provides T-cell modulatory multimeric polypeptide epitope conjugates comprising an immunomodulatory polypeptide (“MOD”) that may be selected to exhibit reduced binding affinity to a cognate co-immunomodulatory polypeptide (“Co-MOD”) and a conjugated Wilms tumor-1 (WT-1) epitope presenting peptide. The T-Cell-MMP-epitope conjugates are useful for modulating the activity of a T-cell by delivering immunomodulatory peptides, such as IL-2 or IL-2 variants that exhibit reduced binding affinity for IL-2R, to the T-cells in a WT-1 epitope selective/specific manner, and accordingly, for treating individuals, particularly those with acute myeloid leukemia, myeloma, ovarian cancer, pancreatic cancer, non-small cell lung cancer, colorectal cancer, breast cancer, Wilms tumor, mesothelioma, soft tissue sarcoma, neuroblastoma, or nephroblastoma. | 2022-01-13 |
20220008468 | ANTI-TUMOR T CELL IMMUNITY INDUCED BY HIGH DOSE RADIATION - Cancer treatment is provided, by irradiating an individual with a localized, high single dose or short course of doses at a primary tumor site; collecting T cells from the individual after a period of time sufficient activation of an anti-tumor response; treating the individual with an effective dose of dose of chemotherapy; and reintroducing the T cell population back to the individual. | 2022-01-13 |
20220008469 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY - The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens. | 2022-01-13 |
20220008470 | RESTIMULATION OF CRYOPRESERVED TUMOR INFILTRATING LYMPHOCYTES - The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation. | 2022-01-13 |
20220008471 | IMMUNOTHERAPY WITH B*08 RESTRICTED PEPTIDES AND COMBINATION OF PEPTIDES AGAINST CANCERS AND RELATED METHODS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2022-01-13 |
20220008472 | IMMUNOTHERAPY WITH B*08 RESTRICTED PEPTIDES AND COMBINATION OF PEPTIDES AGAINST CANCERS AND RELATED METHODS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2022-01-13 |
20220008473 | USE OF CHIMERIC ANTIGEN RECEPTOR T CELLS AND NK CELL INHIBITORS FOR TREATING CANCER - Methods for improving a clinical outcome in a subject comprising administering to a subject in need of the treatment a population of genetically engineered immune cells (e.g., T cells), which express a chimeric antigen receptor (CAR) and a natural killer (NK) cell inhibitor (e.g., daratumumab). The genetically engineered immune cells may comprise a disrupted TRAC gene, a disrupted B2M gene, or both. The disclosure also features compositions for use in the methods. | 2022-01-13 |
20220008474 | ENGINEERED REGULATORY T CELLS - Cell therapy compositions comprising engineered human regulatory T cells (eTregs) characterized by ectopic overexpression of FOXP3 and Helios protein, produced via introduction of separate nucleic acid constructs respectively encoding FOXP3 and Helios (FOXP3+ Helios+ eTregs). Cell therapy compositions comprising mixed populations of CD4+ and CD8+ Treg cells each with ectopic overexpression of FOXP3 and Helios. Methods of making and use the same for therapies involving inflammation and/or a disorder of the immune system. | 2022-01-13 |
20220008475 | METHODS FOR PREPARING PLATELET RELEASATE - The present invention relates to the use of a quantity of one or more water-soluble calcium salts and a quantity of glass particles for preparing platelet releasate from a sample of a platelet-rich blood composition obtained from a subject, wherein said quantity of glass particles is from 0.010 g to 0.60 g per ml of said sample and said quantity of the one or more water-soluble calcium salts is from 1.0 μmol to 12.0 μmol per ml of said sample. Systems and methods for preparing a platelet releasate are also disclosed, as well as the platelet releasate obtained therefrom and the use thereof in in vitro and in vivo applications. | 2022-01-13 |
20220008476 | GENETICALLY ENGINEERED HEMATOPOIETIC STEM CELLS AND USES THEREOF - Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins. | 2022-01-13 |
20220008477 | METHODS AND COMBINATIONS FOR TREATMENT AND T CELL MODULATION - The present disclosure relates in some aspects to methods, compositions and uses involving immunotherapies, such as adoptive cell therapy, e.g., T cell therapy, and an immunomodulatory compound, such as a structural or functional analog or derivative of thalidomide and/or an inhibitor of E3-ubiquitin ligase. The provided methods, compositions and uses include those for combination therapies involving the administration or use of one or more immunomodulatory compounds in conjunction with a T cell therapy, such as a genetically engineered T cell therapy involving cells engineered with a recombinant receptor, such as chimeric antigen receptor (CAR)-expressing T cells. Also provided are compositions, methods of administration to subjects, articles of manufacture and kits for use in the methods. In some aspects, features of the methods and cells provide for increased or improved activity, efficacy, persistence, expansion and/or proliferation of T cells for adoptive cell therapy or endogenous T cells recruited by immunotherapeutic agents. | 2022-01-13 |
20220008478 | EYEDROP APPLICABLE TO LIMBAL STEM CELL DEFICIENCY AND PREPARATION - The present disclosure relates to an eyedrop applicable to limbal stem cell deficiency and a preparation method, wherein each liter of the eyedrop includes the following components: 1 to 40 mg of human adipose-derived stem cell exosomes, excipients: 0.5 to 2 g of sodium hyaluronate, 0.5 to 3 g of vitamin B6 and 0.05 to 0.3 g of benzalkonium chloride, and the balance of medical normal saline, a pH of the eyedrop is 6.5 to 7.5; and the eyedrop of the present disclosure is effective in treating limbal stem cell deficiency. | 2022-01-13 |
20220008479 | Method for Treating Diabetes and Other Glucose Regulation Disorders Using Stem Cells - Various embodiments of the invention provide methods of treating diabetes and other glucose regulation disorders. In one embodiment, the method comprises removing L-cells from a donor, obtaining stem cells from a patient, and culturing the L-cells in the presence of the stem cells under conditions such that the stem cells differentiate into stem cell-derived L-cells (SCDLC). An amount of the SCDLC is introduced into the patient sufficient to cause a lowering of the patient's blood glucose level after ingestion of food. In another embodiment, the method comprises removing K-cells from a donor, obtaining stem cells from a patient, and culturing the K-cells in the presence of the stem cells under conditions such that the stem cells differentiate into stem cell-derived K-cells (SCDKC). An amount of the SCDKC is introduced into the patient sufficient to cause a lowering of the patient's blood glucose level after ingestion of food. | 2022-01-13 |
20220008480 | TRANSGENIC PIG ISLETS AND USES THEREOF FOR TREATING DIABETES - The present invention relates to an isolated transgenic pig beta cell wherein the PKC and the PKA pathway are constitutively activated; to a transgenic pig islet comprising said transgenic pig beta cell; and to a transgenic pig comprising said transgenic pig beta cell or said transgenic pig islet. Another object of the invention is a device comprising a transgenic pig beta cell or a transgenic pig islet of the invention. The present invention also relates to the use of said transgenic pig beta cell, said transgenic pig islet, or said device for treating a disease, disorder or condition related to the impaired function of endocrine pancreas or of beta cell. | 2022-01-13 |
20220008481 | METHOD OF TREATMENT - The present disclosure relates generally to the methods of treatment of mammalian subjects by an enhanced cell-based therapeutic approach in order to facilitate tissue and neuronal repair, regeneration and/or reparation. Medicaments useful in the treatment of mammalian subjects and methods of production of the medicaments are also encompassed by the present disclosure. | 2022-01-13 |
20220008482 | Reprogramming Cells With Synthetic Messenger RNA - Methods for accelerated cell lineage conversion and the treatment of patients with the lineage converted cells are provided. The methods include the steps of transfecting a cell with a composition that includes at least one synthetic mRNA encoding a chimeric protein that corresponds to an engineered fusion of a transcription factor and an heterologous peptide sequence derived from the C-terminal TAD of Gal4. The TAD domain enhances the epigenetic remodeling activity of the chimeric protein increasing the speed of lineage conversion. The converted cells may be used for research or administered to a human or animal patient as a therapy. In one preferred embodiment, the reprogramming of a somatic cell to pluripotency is accelerated by using a cocktail of mRNAs expressing a combination of wild-type or engineered reprogramming factors where Oct4 and/or Sox2 and/or Nanog are expressed as Gal4 TAD chimeras. | 2022-01-13 |
20220008483 | METHOD FOR OBTAINING FREEZE-DRIED ANIMAL SKIN, FREEZE-DRIED ANIMAL SKIN, USE THEREOF AND KIT - The present invention describes a method for obtaining freeze-dried tilapia skin, comprising the steps of cleaning by scraping, washing with physiological saline solution and trimming the edges of the skin; incubation with biocompatible detergent in a sterile recipient and rinsing, incubation with bactericidal agent in sterile recipient and rinsing, incubating with detoxifying solution and rinsing, incubation with antibiotics, rinsing and freezing, cold freeze-drying, vacuum sealing and sterilization, and more specifically the present invention includes the use of tilapia skin to prepare a remedy for treating lesions in humans and animals. The present invention relates to the fields of pharmacy, medicine, dentistry, veterinary medicine, chemistry, biotechnology and tissue engineering. | 2022-01-13 |
20220008484 | PREPARATION AND APPLICATION OF GRAIN WORM FOR TREATING DIABETES - This invention discloses the preparation and the application of Grain Worm for treating diabetes or regulating blood insulin level. The Grain Worm can be in the form of dry powder, tincture, or extracts by itself or in a compound. Grain Worm regulates the blood insulin levels and the human blood glucose level for treating diabetes. It has been discovered that Grain Worm can effectively treat diabetes in humans through reducing insulin resistance and improving the β-cell function. The effect of this agent can last a long period of time (2-5 years). This is the first major discovery of using Grain Worm in treating diabetes. | 2022-01-13 |
20220008485 | Wound Honey - A local honey mixed with a natural preservative concentrate to create a more cost effective medical product. This local product may have the advantageous effect of reducing seasonal allergies and asthma. The product will have the antimicrobial synergistic advantage of combining cinnamaldehyde with vanillin; the synergistic bactericidal process of high pressure processing of a product containing cinnamaldehyde; the synergistic antibacterial effect of combining hydrogen peroxide with organic acids; and the synergistic bactericidal effect of combining cinnamaldehyde with silver nanoparticles. This product will be cheaper than high MGO manuka honey. Additionally, the wound or burn product may also be used as a diagnostic ultrasound gel or sanitizing gel if necessary. | 2022-01-13 |
20220008486 | COMPOSITIONS COMPRISING BACTERIAL STRAINS - The invention provides compositions comprising bacterial strains for treating and preventing inflammatory and autoimmune diseases. | 2022-01-13 |
20220008487 | FAECALIBACTERIUM SP. MICROBE AND ANTICANCER COMPOSITION COMPRISING SAME - The present invention provides a | 2022-01-13 |
20220008488 | PROBIOTICS FOR USE IN THE PREVENTION OR TREATMENT OF ILLNESS AND/OR SYMPTOMS ASSOCIATED WITH CORONAVIRUSES - This invention relates to bacterial strains, compositions comprising bacterial strains as well as methods and uses of said strains and compositions for preventing or treating illness and/or symptoms associated with a coronavirus in a subject in need thereof. | 2022-01-13 |
20220008489 | AGENT FOR IMPROVING MITOCHONDRIAL FUNCTION - The present invention provides a mitochondrial function-improving agent containing a lactic acid bacterium belonging to | 2022-01-13 |
20220008490 | COMPOSITION FOR THE PREVENTION AND TREATMENT OF SKIN DISEASES - A composition is described for the prevention and treatment of skin diseases, in particular in the veterinary field. The composition of the invention includes a synergistic association of Lactobacilli and plant extracts, which has been shown to be significantly effective in supporting the functionality of the skin barrier and restoring homeostasis of microbial populations. In fact, the composition performs a direct action on the skin surface by preventing and contrasting skin alterations, promoting the balance of the microbiota, strengthening the immune system and carrying out antioxidant activity. | 2022-01-13 |
20220008491 | SELECTION OF BACTERIAL STRAINS USEFUL IN ALLERGY TREATMENT - Bacterial strains useful in prophylaxis, inhibition and/or treatment of an allergy in a mammal are selected by screening bacterial strains for capability of producing diacylglycerol kinase (DagK). A bacterial strain which is capable of producing DagK is then selected for use in prophylaxis, inhibition and/or treatment of the allergy. | 2022-01-13 |
20220008492 | EXTRACT OF GINKGO BILOBA LEAVES AND PREPARATION METHOD THEREFOR - The present disclosure provides a | 2022-01-13 |
20220008493 | METHOD FOR INCREASING THC/CBD CONTENT IN A CANNABIS PRODUCT - A method for increasing THC or CBD content, or both, in a cannabis product. | 2022-01-13 |
20220008494 | COMPOSITION FOR USE IN THE PREVENTION AND/OR SYMPTOMATIC TREATMENT OF IRRITABLE BOWEL SYNDROME - A synergistic composition of active ingredients which is particularly effective in the treatment and/or prevention of irritable bowel syndrome is provided. The composition includes the synergistic combination of butyric acid or a salt thereof and | 2022-01-13 |
20220008495 | APPLICATION OF PHLEGMYHEATCLEAR IN PREPARATION OF DRUG FOR TREATMENT OF ACUTE EXACERBATION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE - The invention discloses an application of phlegmyheatclear in preparation of a drug for treatment of acute exacerbation of chronic obstructive pulmonary disease. The present invention studies the effect of phlegmyheatclear on model of rats with acute exacerbation of chronic obstructive pulmonary disease. Results show that high dose, middle dose, or low dose of phlegmyheatclear can, during the acute exacerbation of chronic obstructive pulmonary disease, improve the lung function of the rats and the pathological damage of lung tissues of the rats in different degrees, and it is dose dependent. High dose, middle dose, or low dose of phlegmyheatclear can improve inflammatory reaction in different degrees. For the drug effects, the high dose and the middle dose of phlegmyheatclear are better than the low dose of phlegmyheatclear. Therefore, phlegmyheatclear can be used to prepare a drug for treatment of acute exacerbation of chronic obstructive pulmonary disease. | 2022-01-13 |
20220008496 | ARTIFICIAL TEARS AND THERAPEUTIC USES - The present invention provides ophthalmic compositions, e.g. artificial tears, suitable for treating dry eye syndrome in a human or other mammal suffering there from, e.g. a dog or cat, which comprise a mixture of castor oil with another oil, e.g. a food oil, e. g. olive oil, sesame oil, corn oil etc. | 2022-01-13 |
20220008497 | COMPOSITIONS AND METHODS FOR TREATING SKIN CONDITIONS, ACNE FORM LESIONS, AND ACNE - A topically administered synergistic composition for treating skin conditions, acne form lesions, and acne that simultaneously downregulates the production of TNF alpha, IL-1a, IL-8, Leptin, and Sebum in human skin as well as inhibiting bacterial biofilm growth on human skin as well as inhibition and/or prevention of inflammation in the pilosebaceous unit and/or hair follicle of human skin. | 2022-01-13 |
20220008498 | MULTI-NUTRIENT SUPPLEMENT COMPOSITION AND USES THEREOF - Various embodiments of the invention relate to compositions comprising vitamins, minerals and trace elements, antioxidants, amino acids, probiotics, and other components and methods for using such compositions to treat or prevent diseases associated with oxidative stress, including cardiovascular disease. | 2022-01-13 |
20220008499 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING SEPSIS - There are disclosed herein compositions comprising selepressin for use in treating sepsis in a patient. The composition comprising selepressin may be administered within six hours from when the patient requires vasopressor therapy. The patients may have a serum lactate concentration of less than about 2 mmol/L prior to treatment and/or a ratio of partial pressure arterial oxygen to fraction of inspired oxygen (PaO | 2022-01-13 |
20220008500 | COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE - Methods of treating a subject having heart failure including heart failure with reduced ejection fraction, heart failure with preserved ejection fraction, and left ventricular hypertrophy-induced heart failure. The methods include activating hypothalamic oxytocin neurons in the brain of the subject and/or administering intranasally to the subject a therapeutically effective amount of oxytocin. Intranasal formulations for the treatment of a subject diagnosed with heart failure are also provided. | 2022-01-13 |
20220008501 | Granular Pharmaceutical Composition - The present invention relates to a granular pharmaceutical composition obtained by coating a nucleus with: (1) a layer containing a material having a damp-proofing function, and (2) a drug layer containing linaclotide, a pharmaceutically acceptable salt, or a hydrate thereof, and (3) a layer containing a material having a damp-proofing function. Also, the present invention relates to a method for manufacturing the granular pharmaceutical composition obtained by coating the nucleus with (1) the layer containing the material having a damp-proofing function, (2) the drug layer containing the linaclotide, the pharmaceutically acceptable salt, or the hydrate thereof, and (3) the layer containing the material having a damp-proofing function. | 2022-01-13 |
20220008502 | Method to Treat Alzheimer`s Disease - This document provides methods and materials for treating a mammal having Alzheimer's disease (AD). For example, one or more Zika virus (ZIKV) polypeptides can be administered to a mammal having, or at risk of developing, AD to treat the mammal. | 2022-01-13 |
20220008503 | MATERIALS AND METHODS FOR THE PREVENTION OF RHEUMATOID ARTHRITIS - Compositions and methods for preventing, treating, or delaying the onset of rheumatoid arthritis involving 14-3-3ζ, are described. Provided is a method for preventing, treating, or delaying the onset of rheumatoid arthritis, the method comprising administering an effective amount of 14-3-3ζ, or a variant thereof, to a subject at risk for developing rheumatoid arthritis, and preventing, treating, or delaying the onset of rheumatoid arthritis in the subject. | 2022-01-13 |
20220008504 | METHODS AND COMPOSITIONS FOR TREATMENT OF ABERRANT HEMATOPOIESIS - Embodiments of the present disclosure pertain to methods of reducing hematopoiesis in a subject by administering to the subject a therapeutically effective amount of an inhibitor of Srebp2. Additional embodiments of the present disclosure pertain to compositions for reducing hematopoiesis in a subject. In some embodiments, the compositions include a therapeutically effective amount of an inhibitor of Srebp2. Further embodiments of the present disclosure pertain to methods of enhancing hematopoiesis in a subject by administering to the subject a therapeutically effective amount of an active ingredient. Additional embodiments of the present disclosure pertain to compositions for enhancing hematopoiesis in a subject. In some embodiments, the compositions of the present disclosure include active ingredients that enhance hematopoiesis in the subject. | 2022-01-13 |
20220008505 | Sustained Release Formulations Using Non-Aqueous Emulsions - Non-aqueous emulsion methods for producing polymeric or polymer-coated microparticles are provided. One method produces a sustained release microparticle composition by combining protein powder and a polymer into a hydrocarbon solvent to form a non-aqueous first solution and adding the first solution to a second solution, wherein the second solution comprises a fluorocarbon liquid and a fluorosurfactant to form a non-aqueous emulsion comprising multiple emulsion hydrocarbon droplets in the fluorocarbon liquid. The subsequent microparticle hardening process includes the steps of removing the hydrocarbon solvent from the formed emulsion droplets, which can be achieved through evaporation the hydrocarbon at ambient condition under stirring, or accelerated hardening through vacuum, or through adding hydrofluoroester into the fluorocarbon as a cosolvent. Removing the fluorocarbon liquid and washing with extra fluorocarbon liquid to isolate the sustained release microparticles, wherein the sustained release microparticles comprise one or more cores of protein and a cortex of polymer. | 2022-01-13 |
20220008506 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCER - A pharmaceutical composition contains an antibody or a fragment thereof specific for COL6A3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. A kit includes a container that contains the pharmaceutical composition. A method of producing an antibody or a fragment thereof against a peptide or a MHC/peptide complex. A method for detecting a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a radioisotope and detecting a signal from the radioisotope in the subject. A method for treating a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a toxin. | 2022-01-13 |
20220008507 | METHODS AND COMPOSITIONS FOR TREATMENT OF CORONAVIRUS INFECTION AND ASSOCIATED COAGULOPATHY - The current disclosure provides methods and compositions for treatment of SARS-CoV-2 infection and associated conditions, including COVID-19 Associated Coagulopathy. Certain aspects of the disclosure are directed to methods for treatment of SARS-CoV-2 infection comprising administering a composition comprising a therapeutically effective amount of NAPc2. Further aspects include pharmaceutical compositions comprising NAPc2 and, in some cases, one or more additional anticoagulants. | 2022-01-13 |
20220008508 | RELAXIN RECEPTOR 1 FOR USE IN TREATMENT AND PREVENTION OF HEART FAILURE - The present invention relates to a polynucleotide comprising an expressible nucleic acid sequence encoding a relaxin family peptide receptor (RXFP) polypeptide for use in treatment and/or prevention of heart failure in a subject. The present invention further relates to a vector comprising the polynucleotide of the present invention for use in treatment and/or prevention of heart failure, as well as to host cells, RXFP agonists, kits and devices related thereto. | 2022-01-13 |
20220008509 | PEGYLATED PEPTIDE AMPHIPHILE NANOFIBERS AND METHODS OF USE - Provided herein are peptide amphiphiles (PAs). In some embodiments, provided herein are PEGylated PAs (e.g. nonionic PAs). In some embodiments, the peptide amphiphiles are assembled into nanofibers. The nanofibers may further comprise a growth factor protein, which may bind to a growth factor binding sequence presented on the nonionic PA. In some embodiments, the nanofibers further comprise a charged peptide amphiphile. The charged peptide amphiphile may be bound to a growth factor protein. Further provided herein are methods of use of the peptide amphiphiles and compositions comprising the same, such as for regenerative therapy. | 2022-01-13 |
20220008510 | MANIPULATION OF MENINGEAL LYMPHATIC VASCULATURE FOR BRAIN AND CNS TUMOR THERAPY - A method of inducing lymphangiogenesis in the brain or central nervous system of a subject is provided in which an effective amount of a lymphangiogenesis inducer is administered. A method of inducing lymphangiogenesis in a tumor in the brain or central nervous system of a subject is provided in which an effective amount of a lymphangiogenesis inducer is administered. A method of treating a cancer of the brain or central nervous system is also provided in which an effective amount of a lymphangiogenesis inducer is administered. An example of a lymphangiogenesis inducer is VEGFC. The lymphangiogenesis inducer can be in the form of a protein or a polynucleotide encoding the protein, such as an mRNA or AAV. The lymphangiogenesis inducer can be administered to the cistemamagna or directly into the lymphatic system. An immunotherapeutic agent, such as a checkpoint inhibitor, may also be administered. | 2022-01-13 |
20220008511 | TUMOR TREATMENT USING CYTOKINES AND CANCER DRUGS - This invention discloses a pharmaceutical composition for treating tumors wherein said pharmaceutical comprises a proinflammatory cytokine such as Tumor Necrosis Factor alpha (TNF-a) combined with one or more small molecule cancer drugs within the same liposome. The liposomes are sized to be below 250 nm in diameter to enable them to localize within the tumor due to the Enhanced Permeability and Retention (EPR) effect. This liposomal formulation will ensure that the proinflammatory cytokine and the cancer drug are localized together within the tumor and with less exposure to normal tissues. This invention also discloses that the safety and efficacy of said proinflammatory cytokine/drug liposomes could be further enhanced by coating the exterior of said liposomes with a tumor targeting agent. | 2022-01-13 |
20220008512 | ANTI-CANCER MONOTHERAPY USING SA-4-1BBL - Described herein are methods for treating and preventing cancer. In particular, described herein are methods using SA-4-1BBL as a monotherapy agent to treat, prevent or reduce the risk of cancer, treat, prevent, or reduce the risk of tumorigenesis, and treat, prevent, or reduce the risk of post-surgical tumor recurrence. SA-4-1BBL for use as a monotherapy in such methods also is provided. | 2022-01-13 |
20220008513 | COMBINED TREATMENT OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA - The present invention refers to the combination of an R-CHOP therapy with an administration of NGR-hTNF or an analog thereof for the treatment of primary central nervous system lymphoma, preferably relapsed/refractory primary central nervous system lymphoma. | 2022-01-13 |
20220008514 | COMBINED USE OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS AND HEMATOPOIETIC GROWTH FACTORS FOR TREATING HEMATOPOIETIC DISEASES - The invention relates to the combined use of selective serotonin reuptake inhibitors (SSRIs) and hematopoietic growth factors as a drug and particularly for treating cytopenia related to hematopoietic diseases or chemotherapy, and also to a pharmaceutical kit comprising both SSRIs and hematopoietic growth factors. This combination is more particularly used for treating patients presenting cytopenia, and patients in need of chemotherapy and more particularly to reduce length of chemotherapy-induced aplasia. | 2022-01-13 |
20220008515 | METHOD OF TREATING A TUMOR WITH A COMBINATION OF IL-7 PROTEIN AND AN IMMUNE CHECKPOINT INHIBITOR - The present disclosure relates to methods of treating a cancer (or a tumor) with an IL-7 protein in combination with an immune checkpoint inhibitor, such as a PD-1 antagonist (e.g., anti-PD-1 antibody) or a CTLA-4 antagonist (e.g., anti-CTLA-4 antibody). | 2022-01-13 |
20220008516 | PTH Prodrugs - The present invention relates to PTH prodrugs, pharmaceutical compositions comprising such PTH prodrugs and their uses. | 2022-01-13 |
20220008517 | METHODS FOR TREATING DISEASES ASSOCIATED WITH RESPIRATORY VIRUSES - The present disclosure provides a method of treating a disease associated with a respiratory virus. The method comprises administering an effective amount of a pharmaceutical composition prepared by removing albumin from a solution of a human serum albumin composition and/or comprising a diketopiperazine with amino acid side chains of aspartic acid and alanine (DA-DKP), such as a low molecular weight fraction of human serum albumin. The present disclosure also provides a pharmaceutical product as well as a kit comprising DA-DKP. | 2022-01-13 |
20220008518 | THERAPEUTIC APPROACHES FOR TISSUE RECONSTRUCTION AND WOUND HEALING TREATMENT - Disclosed are compositions containing a therapeutically effective amount of free recombinant or synthetic lubricin, a lubricin-supplemented preserved AM, or a lubricin-supplemented non-AM substrate for promoting tissue reconstruction and wound healing in a subject and the methods of using thereof. Lubricin-supplemented preserved amniotic membranes and lubricin-supplemented non-AM substrates, and methods of preparing thereof are also described. | 2022-01-13 |
20220008519 | TREATMENT OF SEVERE ACUTE RESPIRATORY SYNDROME-RELATED CORONAVIRUS INFECTION WITH KLOTHO - Methods and compositions for treating a severe acute respiratory syndrome-related coronavirus (SARS-CoV) infection in a subject in need are provided. In some aspects, a therapeutically effective amount of a Klotho polypeptide and/or a Klotho polynucleotide encoding a Klotho polypeptide is administered to the subject. In some other aspects, the subject is treated with a first therapy when the subject has diminished Klotho activity, and with a second therapy when the subject does not have diminished Klotho activity. Diminished Klotho activity is determined by comparing the amount of Klotho protein in a blood sample from the subject to a predetermined threshold. In particular, methods and compositions for treating SARS-CoV-2 infection are provided. | 2022-01-13 |
20220008520 | METHODS AND MATERIALS FOR REDUCING AGE-RELATED STRIATED MUSCLE AND COGNITIVE DECLINE - This document provides methods and materials for treating aging. For example, a mammal having, or at risk for developing, an age-related impairment (e.g., age-related cognitive decline) can be treated by increasing the level of one or more myokine polypeptides (e.g., one or more Klotho polypeptides) within cells within the mammal. This document also provides methods and materials for increasing the ability of muscle progenitor cells to regenerate muscle cells by increasing the level(s) of one or more myokine polypeptides (e.g., an α-Klotho polypeptide) within a muscle progenitor cell. | 2022-01-13 |
20220008521 | PHARMACEUTICAL COMPOSITION COMPRISING ANCROD FOR THE TREATMENT OR PROPHYLAXIS OF ENDOCARDITIS - The present invention concerns ancrod for endocarditis prophylaxis or the treatment of endocarditis, especially for the treatment of damage-induced endocarditis. According to the present invention ancrod is preferably administered by intravenous injection, intravenous infusion, intramuscular injection, subcutaneous injection, intraperitoneal injection or combinations thereof. The present invention also concerns pharmaceutical compositions, especially aqueous solutions or dispersions of ancrod for endocarditis prophylaxis or the treatment of endocarditis. | 2022-01-13 |
20220008522 | IMMUNOSUPPRESSIVE ANTIGEN-SPECIFIC CHIMERIC ANTIGEN RECEPTOR TREG CELLS FOR PREVENTION AND/OR TREATMENT OF AUTOIMMUNE AND ALLOIMMUNE DISORDERS - Described herein are immunoresponsive cells which are useful for their preventive and therapeutic potential against autoimmune diseases and rejections of solid organ transplants. | 2022-01-13 |
20220008523 | PEPTIDE CONJUGATED PARTICLES - The present invention provides compositions comprising peptide-coupled biodegradable poly(lactide-co-glycolide) (PLG) particles. In particular, PLG particles are surface-functionalized to allow for coupling of peptide molecules to the surface of the particles (e.g., for use in eliciting induction of immunological tolerance). | 2022-01-13 |
20220008524 | VACCINATION WITH MICROVESICLES DERIVED FROM TUMOUR CELLS FOR CANCER TREATMENT - The present invention relates to microvesicles derived from natural tumor cells and tumor cells produced in vitro under a stress stimulus, such as radiation, which can be used in an effective manner as a therapeutic vaccine for cancer. The invention also relates to a therapeutic vaccine formulation containing the microvesicles, processes for the preparation and medical use thereof as a therapeutic vaccine to stimulate the antitumor immune system and treat cancer. | 2022-01-13 |
20220008525 | CANCER SPECIFIC FRAMESHIFT VACCINES - A method of producing a vaccine for a cancer and/or tumor and stage of interest is disclosed. The method includes identifying a first population of peptides that are immunoreactive with a set of biological samples obtained from a set of test subjects that have been identified as having the cancer and/or tumor of interest, and preparing a cancer vaccine composition for the cancer of interest, wherein the cancer vaccine composition comprises a second population of peptides comprising one or more peptides in the first population or a nucleic acid sequence encoding the one or more peptides, thereby producing the vaccine for the cancer and/or tumor of interest. Also disclosed are vaccine compositions and methods of use thereof. | 2022-01-13 |
20220008526 | METHODS AND COMPOSITIONS FOR CANCER IMMUNOTHERAPY - Disclosed herein are compositions and methods for cancer immunotherapy, and more particularly immune cells loaded with protein clusters and/or immunostimulatory fusion molecules (IFMs), in combination with an inhibitor of a checkpoint inhibitor. | 2022-01-13 |
20220008527 | Heat Shock Protein-Binding Peptide Compositions And Methods Of Use Thereof - Provided are polypeptides and compositions comprising novel HSP-binding peptides. Such polypeptides and compositions are particularly useful as immunotherapeutics (e.g., cancer vaccines). Also provided are methods of inducing a cellular immune response using such polypeptides and compositions, methods of treating a disease using such polypeptides and compositions, kits comprising such polypeptides and compositions, and methods of making such compositions. | 2022-01-13 |
20220008528 | COMPOSITION FOR PREVENTING OR TREATING BENIGN TUMOR - The present disclosure provides a composition for preventing or treating a benign tumor. Provided is a composition for preventing or treating a benign tumor that comprises a WT1 peptide or an analog thereof, or a nucleic acid molecule encoding a WT1 peptide or an analog thereof. In a specific embodiment, the present disclosure provides a composition for preventing or treating a benign tumor that comprises a WT1 peptide or an analog thereof, or a nucleic acid molecule encoding a WT1 peptide or an analog thereof. In a preferred embodiment, the composition for preventing or treating a benign tumor (e.g. familial adenomatous polyposis) according to the present disclosure comprises a killer type WT1 peptide and/or a helper type WT1 peptide. In a further preferred embodiment, the WT1 peptide is WT1 | 2022-01-13 |
20220008529 | MULTI-FUNCTIONALIZED noMV CONJUGATES - The present invention is in the field of conjugating native, non-detergent extracted, outer membrane vesicles (nOMV) to multiple antigens to form multi functionalized nOMV-antigen conjugated derivatives, which are particularly useful for immunogenic compositions and immunisation; processes for the preparation and use of such conjugates are also provided. | 2022-01-13 |
20220008530 | MERS-CoV VACCINE COMPOSITION - An immunogenic CD40-targeted trimeric MERS-CoV S1 fusion polypeptide as well as a corresponding polynucleotide encoding it and its use for safely inducing immune responses directed against MERS-CoV without inducing vaccine associated respiratory pathologies associated with non-targeted vaccines. | 2022-01-13 |
20220008531 | INTRANASAL MERS-CoV VACCINE - An immunogenic CD40-targeted trimeric MERS-CoV S1 fusion polypeptide as well as a corresponding polynucleotide encoding it and its use for safely inducing immune responses directed against MERS-CoV without inducing vaccine associated respiratory pathologies associated with non-targeted vaccines. | 2022-01-13 |
20220008532 | MULTIVALENT FELINE VACCINE - The present invention provides new multivalent vaccines for felines. The present invention also provides methods of making and using the multivalent vaccines alone or in combinations with other protective agents. | 2022-01-13 |
20220008533 | COMPOSITION AND METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES - This invention relates to methods of treating disorders such as celiac disease by administrating anti-CD3 antibodies alone or in combination with additional agents. | 2022-01-13 |
20220008534 | Combination Of Local And Systemic Immunomodulative Therapies For Enhanced Treatment of Cancer - A method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic immunomodulatory anticancer agent. A further method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic targeted anticancer agent. The present invention is further directed to pharmaceutical compositions for treatment of cancer. The intralesional chemoablative pharmaceutical composition can comprise an IL chemoablative agent comprising primarily a halogenated xanthene. | 2022-01-13 |
20220008535 | METHODS AND COMPOSITIONS FOR THE TREATMENT AND/OR PREVENTION OF TYPE 1 DIABETES - The disclosure relates generally to methods and compositions of treating or preventing diabetes mellitus by administering to a subject a composition comprising an amount of stem and/or progenitor cells and at least one antigen-specific therapy. | 2022-01-13 |
20220008536 | STABLE LIQUID COMPOSITION COMPRISING PROTEIN - Disclosed is a stable liquid formulation of a protein. Provided is a liquid protein composition comprising a protein, and being free of a buffer and/or comprising histidine, and a preparation method thereof. | 2022-01-13 |
20220008537 | COMPOUNDS FOR PHOTODYNAMIC THERAPY AND RELATED USES - Disclosed herein are symmetrical and unsymmetrical carbocyanine dyes. Irradiation of the dyes generates reactive species which contribute to DNA damage. The dyes are useful for the treatment of various cancers and cell growth disorders. | 2022-01-13 |
20220008538 | METHODS FOR PHOTODYNAMIC THERAPY - A method of enhancing penetration of a topical composition of 5-aminolevulinic acid (ALA) into tissue for photodynamic therapy includes topically applying ALA to a treatment area to be treated with photodynamic therapy. The method further includes, after the ALA is applied to the treatment area, covering the treatment area with a low density polyethylene barrier. The treatment area is covered with the low density polyethylene barrier prior to light treatment to minimize transepidermal water loss from the treatment area. | 2022-01-13 |
20220008539 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM - Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T | 2022-01-13 |
20220008540 | METHODS OF TREATING OR PREVENTING STENT THROMBOSIS - The present invention is directed to the following: methods of treating or preventing stent thrombosis using pharmaceutical compositions comprising cangrelor and optionally bivalirudin; methods of reducing mortality in a subject undergoing stent implantation using pharmaceutical compositions comprising cangrelor and optionally bivalirudin; medicaments comprising cangrelor and optionally bivalirudin useful for treating or preventing stent thrombosis, or useful for reducing mortality in a subject undergoing stent implantation; pharmaceutical compositions comprising cangrelor and bivalirudin; and methods of preparing a medicament comprising cangrelor and optionally bivalirudin useful for treating or preventing stent thrombosis, or useful for reducing mortality in a subject undergoing stent implantation. | 2022-01-13 |
20220008541 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES - The present invention provides a phosphorothioate-modified oligonucleotide comprising a structure shown below: | 2022-01-13 |
20220008542 | ANTI-PROTOZOAL COMPOUNDS AND USES THEREOF - The present disclosure provides veterinary formulations comprising a therapeutically effective amount of an antiprotozoal compound and a polymer. The disclosure also provides methods of treating trichomoniasis in a bovine and methods of treating a | 2022-01-13 |
20220008543 | MACROMOLECULAR PRODRUG-BASED THERMOSENSITIVE INJECTABLE GEL AS A NOVEL DRUG DELIVERY PLATFORM - This application discloses prodrug-based thermosensitive gel (“ProGel”) comprised of conjugates of dmg molecules with water-soluble polymeric carriers, which are capable of controlled release of the dmg molecules into the tissue of a subject. Use of the ProGel-Drug conjugates for treatment of various diseases or disorders and methods of preparing them are also disclosed. | 2022-01-13 |
20220008544 | METHODS OF TREATING MULTIPLE MYELOMA CANCERS EXPRESSING HIGH LEVELS OF EPO-RECEPTOR USING PSA-EPO - The present invention demonstrates that erythropoietin (EPO)-receptor (EPOR) is a malignant myeloma biomarker of sensitivity to EPO treatment and, itself a target for myeloma treatment. A low EPOR level in a myeloma cells of the subject indicates non-response to EPO treatment. Patients having high EPOR level in myeloma cells can be effectively treated with EPO, in particular an EPO derivatized with polysialic acid. | 2022-01-13 |
20220008545 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR FAPa - The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of fibroblast activation protein a (FAPα). The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by FAPα. | 2022-01-13 |
20220008546 | POLYPEPTIDE-BASED OCULAR ABSORPTION ENHANCER AND APPLICATION THEREOF - The present disclosure belongs to the field of pharmaceutical preparations and relates to the design of a series of lipophilic derivatives by using wild-type penetrating peptide penetratin. These penetratin derivatives have a strong ability to penetrate the ocular tissues and do not cause ocular tissue toxicity. As ocular absorption enhancers, non-invasive routes could be used to achieve intraocular drug delivery and increase the ocular bioavailability of drugs. These penetratin derivatives and the ophthalmic drug delivery system constructed by them are used for eye drop administration, which could replace the intraocular injection with poor patients compliance, which greatly enhances the convenience and safety of the treatment of intraocular and fundus diseases. | 2022-01-13 |
20220008547 | Carrier Peptide Fragment and use Thereof - A method of introducing a foreign substance from the outside of eukaryotic cells into at least a cytoplasm of the cells in vitro or in vivo disclosed here includes the following steps:
| 2022-01-13 |
20220008548 | MULTISPECIFIC ANTIGEN-BINDING MOLECULES AND USES THEREOF - The present invention provides multispecific antigen-binding molecules and uses thereof. The multispecific antigen-binding molecules comprise a first antigen-binding domain that specifically binds a target molecule, and a second antigen-binding domain that specifically binds an internalizing effector protein. The multispecific antigen-binding molecules of the present invention can, in some embodiments, be bispecific antibodies that are capable of binding both a target molecule and an internalizing effector protein. In certain embodiments of the invention, the simultaneous binding of the target molecule and the internalizing effector protein by the multispecific antigen-binding molecule of the present invention results in the attenuation of the activity of the target molecule to a greater extent than the binding of the target molecule alone. In other embodiments of the invention, the target molecule is a tumor associated antigen, and the simultaneous binding of the tumor associated antigen and the internalizing effector protein by the multispecific antigen-binding molecule of the present invention causes or facilitates the targeted killing of tumor cells. | 2022-01-13 |
20220008549 | NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF - Desired is development of novel CDN derivatives having STING agonist activity; and a therapeutic agents and/or therapeutic methods using the novel CDN derivatives for diseases associated with STING agonist activity. Further desired is development of a therapeutic agents and/or therapeutic methods capable of delivering the novel CDN derivatives specifically to targeted cells and organs for diseases associated with STING agonist activity. The present invention provides novel CDN derivatives having potent STING agonist activity, and antibody-CDN derivative conjugates including the novel CDN derivatives. | 2022-01-13 |
20220008550 | COMPOSITIONS AND METHODS OF TREATING MUSCLE ATROPHY AND MYOTONIC DYSTROPHY - Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating muscle atrophy or myotonic dystrophy. | 2022-01-13 |
20220008551 | POLYPEPTIDE CONJUGATES - Disclosed herein is are conjugates that comprise a ubiquitin dimer or multimer, comprising a distal moiety conjugated to a proximal moiety. The distal moiety comprises a polypeptide comprising a distal ubiquitin at its C-terminus, said ubiquitin comprising at least one of the following mutations: K6X, K11X, K27X, K29X, K33X, K48X, K48X, K63X, or K63X, where X is selected from R, A or C. The proximal moiety comprises a polypeptide comprising either a proximal ubiquitin at its C-terminus or a proximal ubiquitin at its N-terminus; said ubiquitin comprising a blocked C-terminus. The distal moiety is conjugated to the proximal moiety via an amide bond from G76 of the distal ubiquitin to one of M1, K6, K11, K27, K29, K33, K48, or K63 of the proximal ubiquitin. Also provided are methods for the production of said conjugates, formulations comprising said conjugates and methods of using said conjugates. | 2022-01-13 |
20220008552 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES - A conjugate of formula (I): | 2022-01-13 |
20220008553 | ANTI-ERBB2 ANTIBODY-DRUG CONJUGATE AND COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF - Provided is a method for the prophylaxis or treatment of cancer, comprising administering to a patient in need thereof an antibody-drug conjugate represented by Formula (I), or a pharmaceutically acceptable salt or stereoisomer thereof, or a solvate of the foregoing, | 2022-01-13 |
20220008554 | NOVEL NANOPARTICLES OF ANTIRETROVIRAL DRUGS, THEIR PREPARATION AND THEIR USE FOR THE TREATMENT OF VIRAL INFECTIONS - The present application relates to nanoparticles including an antiretroviral drug and chitosan and optionally one or more metal cation, their use for treating viral infections, their process of preparation and the pharmaceutical compositions including the same. | 2022-01-13 |
20220008555 | PREPARATION OF SOLID CYCLODEXTRIN COMPLEXES FOR OPHTHALMIC ACTIVE PHARMACEUTICAL INGREDIENT DELIVERY - The present disclosure relates to ophthalmic compositions containing solid complexes of active pharmaceutical ingredient and cyclodextrin, to their method of preparation and their uses. The compositions can include an active agent drug/cyclodextrin complex substantially dissolved in an aqueous eye drop vehicle. The ophthalmic composition is generally in the form of a microsuspension including an active agent complex having a diameter of less than about 100 μm. | 2022-01-13 |
20220008556 | DNA VECTOR FOR TARGETED GENE THERAPY - The invention relates to biotechnology, to gene therapy DNA vectors, a | 2022-01-13 |
20220008557 | FUSOSOME COMPOSITIONS FOR CNS DELIVERY - The present disclosure provides, at least in part, methods and compositions for in vivo fusosome delivery. In some embodiments, the fusosome comprises a combination of elements that promote specificity for target cells, e.g., one or more of a fusogen, a positive target cell-specific regulatory element, and a non-target cell-specific regulatory element. In some embodiments, the fusosome comprises one or more modifications that decrease an immune response against the fusosome. | 2022-01-13 |
20220008558 | MATERIALS AND METHODS FOR TREATMENT OF HEREDITARY HAEMOCHROMATOSIS - Materials and methods for treating a patient with hereditary hemochromatosis (HHC), both ex vivo and in vivo, and materials and methods for modulating the expression, function, or activity of a haemochromatosis (HFE) gene in a cell by genome editing. | 2022-01-13 |
20220008559 | NUCLEIC ACID CONSTRUCTS AND GENE THERAPY VECTORS FOR USE IN THE TREATMENT OF WILSON DISEASE - The invention relates to nucleic acid constructs and gene therapy vectors that comprise an ATP7B variant for use in the treatment of conditions associated with a deficiency or dysfunction of Copper-transporting ATPase 2, and particularly of Wilson's disease. An AAV vector devised according to the invention significantly reduced urine Cu excretion, and liver Cu content in Wilson's disease mice treated with the vector, while ceruloplasmin activity was significantly restored. On the other hand, the administration of the vector resulted in the normalization of serum transaminases' levels and of liver histology, together with a marked reduction of the inflammatory infiltrate. | 2022-01-13 |
20220008560 | TREATMENT OF HEART DISEASE BY DISRUPTION OF THE ANCHORING OF PP2A - The present invention provides a method of treating heart failure with reduced ejection fraction, by administering to a patient at risk of such damage, a pharmaceutically effective amount of a composition which inhibits the anchoring of PP2A to mAKAPβ. This composition is preferably in the form of a viral based gene therapy vector that encodes a fragment of mAKAPβ to which PP2A binds. | 2022-01-13 |
20220008561 | BISMUTH METAL-ORGANIC FRAMEWORKS FOR USE AS X-RAY COMPUTED TOMOGRAPHY CONTRAST AGENTS - Metal-organic frameworks with bismuth cluster nodes (Bi-MOFs) and methods of using the Bi-MOFs as contrast agents in medical imaging systems, such as computerized tomography (CT) systems, are provided. Contrast compositions that include the Bi-MOFs in a carrier in forms suitable for administration to a patient are also provided. The Bi-MOFs include those with Bi | 2022-01-13 |
20220008562 | FORMULATION OF CONTRAST MEDIA AND PROCESS OF PREPARATION THEREOF - The present disclosure relates to a liquid pharmaceutical formulation comprising a DOSA-derived tetra-chelate of formula (I), in which M is an ion of a paramagnetic metal, preferably a Gd | 2022-01-13 |
20220008563 | RADIOLABELLED AND NONRADIOLABELLED PEGYLATED COMPOUNDS AND USES THEREOF - The disclosure provides compounds for detecting neurodegeneration and/or identifying and monitoring the progression of inflammation in neurodegenerative diseases. The disclosure further provides compounds that inhibit the activity of monoamine oxidases, and uses thereof. | 2022-01-13 |
20220008564 | RADIOPHARMACEUTICAL AND METHODS - The radiopharmaceutical | 2022-01-13 |
20220008565 | Enhanced in Vivo Targeting of Site-Specific Drugs - The present invention relates to a compound that inhibits the activity of a degrading enzyme for use in combination with a therapeutic or diagnostic compound, preferably a moiety conjugated peptide, in the diagnosis and/or treatment of a disease, in particular cancer, to enhance targeting of the therapeutic or diagnostic compound to the disease site. | 2022-01-13 |
20220008566 | Pharmaceutical Composition Comprising a Radiolabeled GRPR Antagonist and a Surfactant - The present disclosure relates to gastrin-releasing peptide receptor (GRPR) targeting radiopharmaceuticals and uses thereof. In particular, the present disclosure relates to a pharmaceutical composition comprising radiolabeled GRPR-antagonist and a surfactant. The present disclosure also relates to radiolabeled GRPR-antagonist for use in treating or preventing a cancer. | 2022-01-13 |